Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 6/20 | 0.61 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15431568 | 0.91 | IRAK1 (0.54) | IRAK1FGFR3KDRHPGDSGPR119 | |
| SCHEMBL15431560 | 0.90 | GPR119 (0.55) | IRAK1FGFR3KDRHPGDSGPR119 | |
| SCHEMBL16713499 | 0.89 | IRAK4 (0.54) | IRAK1IRAK4 | |
| SCHEMBL15431627 | 0.89 | IRAK4 (0.54) | IRAK1IRAK4 | |
| SCHEMBL15416742 | 0.89 | IRAK4 (0.54) | IRAK1IRAK4 | |
| SCHEMBL16899762 | 0.88 | IRAK4 (0.48) | IRAK1IRAK4 | |
| SCHEMBL15416148 | 0.87 | IRAK1 (0.54) | IRAK1FGFR3KDRHPGDSGPR119 | |
| SCHEMBL15431358 | 0.87 | IRAK1 (0.54) | IRAK1FGFR3KDRHPGDSGPR119 | |
| SCHEMBL15416149 | 0.87 | IRAK1 (0.54) | IRAK1FGFR3KDRHPGDSGPR119 | |
| SCHEMBL20280701 | 0.86 | MET (0.52) | IRAK1FGFR3KDRHPGDSGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10314841-B2 | Substituted pyrazoles as IRAK inhibitors | MERCK PATENT GMBH (DE) | 2019-06-11 | — | — | US | disclosed |
| US-10314841-B2 | Substituted pyrazoles as IRAK inhibitors | MERCK PATENT GMBH (DE) | 2019-06-11 | — | — | US | disclosed |
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| EP-3092225-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | Merck Patent GmbH (DE) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015106058-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106058-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | IRAK2, IRAK3, IRAK1 | IRAK1 3/4885FGFR3 800/4885KDR 1201/4885 |
| US-10314841-B2 | Substituted pyrazoles as IRAK inhibitors | IRAK2, IRAK3, IRAK1 | IRAK1 3/4885FGFR3 735/4885KDR 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.